ERK inhibition in glioblastoma is associated with autophagy activation and tumorigenesis suppression-Reference-Cited by-同舟云学术

ERK inhibition in glioblastoma is associated with autophagy activation and tumorigenesis suppression

Published:2021-11-19 Issue:1 Volume:156 Page:123-137
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Yang Kang,Luan Lan,Li Xinyu,Sun Xu,Yin Jian^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11060-021-03896-3.pdf

Reference59 articles.

1. Diamandis P, Aldape K (2018) World Health Organization 2016 classification of central nervous system tumors. Neurol Clin 36:439–447. https://doi.org/10.1016/j.ncl.2018.04.003

2. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21:v1–v100. https://doi.org/10.1093/neuonc/noz150

3. Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R (2019) Newly diagnosed glioblastoma: a review on clinical management. Oncology 33:91–100

4. Carlsson SK, Brothers SP, Wahlestedt C (2014) Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med 6:1359–1370. https://doi.org/10.15252/emmm.201302627

5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance;Cancer Letters;2024-08

2. Role of Scaffold Proteins in the Heterogeneity of Glioblastoma;2024-07-29

3. ZBTB20 suppresses tumor growth in glioblastoma through activating the TET1/FAS/caspase‑3 pathway;Oncology Letters;2024-06-05

4. DNA damage-regulated autophagy modulator 1 prevents glioblastoma cells proliferation by regulating lysosomal function and autophagic flux stability;Experimental Cell Research;2024-04

5. Autophagy machinery in glioblastoma: The prospect of cell death crosstalk and drug resistance with bioinformatics analysis;Cancer Letters;2024-01